
Head and neck cancer (HNC) and its treatments can pose significant psychosocial challenges for survivors, including feelings of shame and stigma, which can worsen quality of life and survivorship. We aimed to test the psychometric properties of the Chilean Spanish version of the shame and stigma scale on a sample of head and neck cancer survivors. Methods: The SSS is a 20-item self-administered questionnaire that assesses shame and stigma associated with HNC. A cross-sectional, descriptive, psychometric validation study was conducted in a private non-profit cancer centre in Santiago de Chile. Participants were over 18 years of age who finished active treatment for HNC at any stage, were fluent in Spanish and were cognitively able to participate. Reliability was analysed using Cronbach’s alpha, and confirmatory factor analysis (CFA) was performed following the model of the original scale. Results: A total of 120 HNC survivors participated in the study (39% women). The median age was 63 years. The reliability analysis yielded a value of alpha = 0.92 (IC = 0.89–0.94), leading to the removal of one item to optimise internal consistency. Confirmatory factor analysis using the robust weighted least squares estimator with a one-factor structure yielded a Comparative Fit Index (CFI) of 0.984, a Root Mean Square Error of Approximation (RMSEA) of 0.098, a Standardised Root Mean Square Residual (SRMR) of 0.112 and a Tucker-Lewis Index (TLI) of 0.982. The four-factor model showed improved fit indices, with CFI = 0.997, RMSEA = 0.044, SRMR = 0.089 and TLI = 0.996, suggesting that the four-factor structure provides a better representation of the data under estimation. Conclusion: SSS-Sp is psychometrically
We investigated the evidence base of Clinical Practice Guidelines (CPGs) on 10 major cancers from mainland China, the Hong Kong Special Administrative Region and Taiwan. We sought information about the delays between publication of the CPGs and their respective references, the geographical origins of the research reported in these references and the sources of funding for this research. We identified 396 CPGs from China, 42 from Hong Kong and 54 from Taiwan for ten major cancers, and 12,556, 3,652, and 4,485 references to these CPGs in the three territories, respectively. We determined the countries of the authors (for the non-Chinese references) and the Chinese provinces or cities (for the references in Chinese) and also analysed the funding sources for the research. Some 22% of the references cited in the CPGs from China were in Chinese, and some of their references were based on Traditional Chinese Medicine (TCM), particularly in mainland China and for gastrointestinal cancers. The references in the Chinese CPGs tended to cite Chinese research less than expected, but Japanese research rather more – as did the references in the Hong Kong and Taiwanese CPGs, which over-cited research from their own territories. The sources of financial support for the international references were mainly public grant-giving bodies and pharmaceutical companies from the USA, Japan and Europe, rather than the main Chinese governmental funders. The rapidly increasing Chinese cancer research output will make the latter funding sources more important in future, and they may also be expected to influence the evidence base of the Hong Kong and Taiwanese CPGs. However, since Chinese cancer research is very basic (rather than clinical), its direct influence on cancer care is likely to be less than might be expected.